文献速递小儿麻醉心胸血管麻醉

右美托咪定在婴儿心脏矫治手术中的1期多中心研究结果

Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery.
PubMed 文献 · Br J Anaesth · 2019-10-14

这项1期多中心研究纳入122例0-180天接受体外循环心脏手术的婴儿,评估右美托咪定(DEX)的安全性、药代动力学(PK)并建立PK模型与剂量方案。结果显示不良安全事件发生率为4.1%(95%CI 1.8-9.2%),体外循环后DEX清除率为1240 ml min-1 70 kg-1,模型验证中96.1%的实测浓度落在5th-95th百分位预测区间内,并推荐了稳态血浆浓度200-1000 pg ml-1的剂量策略。

要点

  • 婴儿体外循环心脏手术中右美托咪定不良安全事件发生率为4.1%。
  • 体外循环后DEX清除率为1240 ml min-1 70 kg-1。
  • 模型验证中96.1%实测浓度落在5th-95th百分位预测区间内。

核心结论

  • 采用谨慎剂量策略时,右美托咪定在婴儿体外循环心脏手术中不良安全事件发生率低且严重程度轻。
  • 该验证过的PK模型有助于临床医生选择合适的剂量。
  • 本1期试验结果为右美托咪定神经保护的3期试验提供了初步数据。

研究设计与样本

  • 1期多中心研究,纳入122例0-180天患有D型大动脉转位、室间隔缺损或法洛四联症的婴儿。
  • 采用剂量递增进行NONMEM® PK建模,随后进行验证以达到低(200-300 pg ml-1)、中(400-500 pg ml-1)、高(600-700 pg ml-1)DEX血浆浓度。

主要发现

  • 122例受试者中5例发生不良安全结局(4.1%;95%CI 1.8-9.2%)。
  • 不良事件包括2例交界性心律、2例二度/三度房室传导阻滞和1例低血压。
  • 术后即刻清除率(CL)和体外循环(CPB)期间CL分别较CPB前CL降低约50%和95%。
  • CPB后DEX清除率为1240 ml min-1 70 kg-1。
  • 达到50%最大清除率的年龄约为2天,达到90%最大清除率的年龄为18天。

关键数值与推荐

  • 推荐剂量策略用于稳态DEX血浆浓度范围200至1000 pg ml-1。

临床怎么用

  • 临床可依据验证的PK模型选择剂量,以达到目标稳态DEX血浆浓度。
  • 在婴儿体外循环心脏手术中使用右美托咪定时应采用谨慎剂量策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexmedetomidine (DEX) is increasingly used intraoperatively in infants undergoing cardiac surgery. This phase 1 multicentre study sought to: (i) determine the safety of DEX for cardiac surgery with cardiopulmonary bypass; (ii) determine the pharmacokinetics (PK) of DEX; (iii) create a PK model and dosing for steady-state DEX plasma levels; and (iv) validate the PK model and dosing. METHODS: We included 122 neonates and infants (0-180 days) with D-transposition of the great arteries, ventricular septal defect, or tetralogy of Fallot. Dose escalation was used to generate NONMEM® PK modelling, and then validation was performed to achieve low (200-300 pg ml-1), medium (400-500 pg ml-1), and high (600-700 pg ml-1) DEX plasma concentrations. RESULTS: Five of 122 subjects had adverse safety outcomes (4.1%; 95% confidence interval [CI], 1.8-9.2%). Two had junctional rhythm, two had second-/third-degree atrioventricular block, and one had hypotension. Clearance (CL) immediately postoperative and CL on CPB were reduced by approximately 50% and 95%, respectively, compared with pre-CPB CL. DEX clearance after CPB was 1240 ml min-1 70 kg-1. Age at 50% maximum clearance was approximately 2 days, and that at 90% maximum clearance was 18 days. Overall, 96.1% of measured DEX concentrations fell within the 5th-95th percentile prediction intervals in the PK model validation. Dosing strategies are recommended for steady-state DEX plasma levels ranging from 200 to 1000 pg ml-1. CONCLUSIONS: When used with a careful dosing strategy, DEX results in low incidence and severity of adverse safety events in infants undergoing cardiac surgery with cardiopulmonary bypass. This validated PK model should assist clinicians in selecting appropriate dosing. The results of this phase 1 trial provide preliminary data for a phase 3 trial of DEX neuroprotection. CLINICAL TRIALS REGISTRATION: NCT01915277.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Zuppa AF, Nicolson SC, Wilder NS, et al. Results of a phase 1 multicentre investigation of dexmedetomidine bolus and infusion in corrective infant cardiac surgery. Br J Anaesth. 2019. PMID: 31623840. doi:10.1016/j.bja.2019.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。